112 related articles for article (PubMed ID: 22770227)
1. Breast density change as a predictive surrogate for response to adjuvant endocrine therapy in hormone receptor positive breast cancer.
Kim J; Han W; Moon HG; Ahn S; Shin HC; You JM; Han SW; Im SA; Kim TY; Koo H; Chang J; Cho N; Moon W; Noh DY
Breast Cancer Res; 2012 Jul; 14(4):R102. PubMed ID: 22770227
[TBL] [Abstract][Full Text] [Related]
2. Determinants of Weight Gain During Adjuvant Endocrine Therapy and Association of Such Weight Gain With Recurrence in Long-term Breast Cancer Survivors.
Raghavendra A; Sinha AK; Valle-Goffin J; Shen Y; Tripathy D; Barcenas CH
Clin Breast Cancer; 2018 Feb; 18(1):e7-e13. PubMed ID: 29239836
[TBL] [Abstract][Full Text] [Related]
3. Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?
Wimmer K; Hlauschek D; Balic M; Pfeiler G; Greil R; Singer CF; Halper S; Steger G; Suppan C; Gampenrieder SP; Helfgott R; Egle D; Filipits M; Jakesz R; Sölkner L; Fesl C; Gnant M; Fitzal F
Breast Cancer Res Treat; 2024 Jun; 205(2):227-239. PubMed ID: 38273214
[TBL] [Abstract][Full Text] [Related]
4. The POWER-PAK Score Characterizes Tumor Response to 3 Months of Preoperative Endocrine Therapy.
Meneveau MO; Crawford MP; Turkheimer LM; Millard TA; Atkins KA; Showalter SL
Ann Surg Oncol; 2023 Oct; 30(10):6034-6040. PubMed ID: 37454014
[TBL] [Abstract][Full Text] [Related]
5. The Potential for Mammographic Breast Density Change as a Biosensor of Adjuvant Tamoxifen Therapy Adherence and Response.
Mullooly M; Gierach GL
JNCI Cancer Spectr; 2018 Nov; 2(4):pky072. PubMed ID: 30746510
[No Abstract] [Full Text] [Related]
6. Adjuvant tamoxifen-induced mammographic breast density reduction as a predictor for recurrence in estrogen receptor-positive premenopausal breast cancer patients.
Ko KL; Shin IS; You JY; Jung SY; Ro J; Lee ES
Breast Cancer Res Treat; 2013 Dec; 142(3):559-67. PubMed ID: 24233999
[TBL] [Abstract][Full Text] [Related]
7. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).
Cardoso F; Costa A; Norton L; Senkus E; Aapro M; André F; Barrios CH; Bergh J; Biganzoli L; Blackwell KL; Cardoso MJ; Cufer T; El Saghir N; Fallowfield L; Fenech D; Francis P; Gelmon K; Giordano SH; Gligorov J; Goldhirsch A; Harbeck N; Houssami N; Hudis C; Kaufman B; Krop I; Kyriakides S; Lin UN; Mayer M; Merjaver SD; Nordström EB; Pagani O; Partridge A; Penault-Llorca F; Piccart MJ; Rugo H; Sledge G; Thomssen C; Van't Veer L; Vorobiof D; Vrieling C; West N; Xu B; Winer E; ;
Breast; 2014 Oct; 23(5):489-502. PubMed ID: 25244983
[No Abstract] [Full Text] [Related]
8. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†.
Cardoso F; Costa A; Norton L; Senkus E; Aapro M; André F; Barrios CH; Bergh J; Biganzoli L; Blackwell KL; Cardoso MJ; Cufer T; El Saghir N; Fallowfield L; Fenech D; Francis P; Gelmon K; Giordano SH; Gligorov J; Goldhirsch A; Harbeck N; Houssami N; Hudis C; Kaufman B; Krop I; Kyriakides S; Lin UN; Mayer M; Merjaver SD; Nordström EB; Pagani O; Partridge A; Penault-Llorca F; Piccart MJ; Rugo H; Sledge G; Thomssen C; Van't Veer L; Vorobiof D; Vrieling C; West N; Xu B; Winer E
Ann Oncol; 2014 Oct; 25(10):1871-1888. PubMed ID: 25234545
[No Abstract] [Full Text] [Related]
9. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.
Jeselsohn R; Yelensky R; Buchwalter G; Frampton G; Meric-Bernstam F; Gonzalez-Angulo AM; Ferrer-Lozano J; Perez-Fidalgo JA; Cristofanilli M; Gómez H; Arteaga CL; Giltnane J; Balko JM; Cronin MT; Jarosz M; Sun J; Hawryluk M; Lipson D; Otto G; Ross JS; Dvir A; Soussan-Gutman L; Wolf I; Rubinek T; Gilmore L; Schnitt S; Come SE; Pusztai L; Stephens P; Brown M; Miller VA
Clin Cancer Res; 2014 Apr; 20(7):1757-1767. PubMed ID: 24398047
[TBL] [Abstract][Full Text] [Related]
10. The influence of the treatment response on the impact of resection margin status after preoperative chemoradiotherapy in locally advanced rectal cancer.
Lee JH; Chie EK; Kim K; Jeong SY; Park KJ; Park JG; Kang GH; Han SW; Oh DY; Im SA; Kim TY; Bang YJ; Ha SW
BMC Cancer; 2013 Dec; 13():576. PubMed ID: 24304825
[TBL] [Abstract][Full Text] [Related]
11. Relationship between mammographic density and breast cancer death in the Breast Cancer Surveillance Consortium.
Gierach GL; Ichikawa L; Kerlikowske K; Brinton LA; Farhat GN; Vacek PM; Weaver DL; Schairer C; Taplin SH; Sherman ME
J Natl Cancer Inst; 2012 Aug; 104(16):1218-27. PubMed ID: 22911616
[TBL] [Abstract][Full Text] [Related]
12. Mammographic density reduction is a prognostic marker of response to adjuvant tamoxifen therapy in postmenopausal patients with breast cancer.
Li J; Humphreys K; Eriksson L; Edgren G; Czene K; Hall P
J Clin Oncol; 2013 Jun; 31(18):2249-56. PubMed ID: 23610119
[TBL] [Abstract][Full Text] [Related]
13. Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years.
Brentnall AR; Warren R; Harkness EF; Astley SM; Wiseman J; Fox J; Fox L; Eriksson M; Hall P; Cuzick J; Evans DG; Howell A
Breast Cancer Res; 2020 Sep; 22(1):101. PubMed ID: 32993747
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Therapy and Mammographic Density Changes in Women With Breast Cancer.
Eriksson L; He W; Eriksson M; Humphreys K; Bergh J; Hall P; Czene K
JNCI Cancer Spectr; 2018 Oct; 2(4):pky071. PubMed ID: 31360886
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal Changes in Volumetric Breast Density with Tamoxifen and Aromatase Inhibitors.
Engmann NJ; Scott CG; Jensen MR; Ma L; Brandt KR; Mahmoudzadeh AP; Malkov S; Whaley DH; Hruska CB; Wu FF; Winham SJ; Miglioretti DL; Norman AD; Heine JJ; Shepherd J; Pankratz VS; Vachon CM; Kerlikowske K
Cancer Epidemiol Biomarkers Prev; 2017 Jun; 26(6):930-937. PubMed ID: 28148596
[No Abstract] [Full Text] [Related]
16. Bone mineral density fall during aromatase inhibitor treatment may predict lower breast cancer recurrence.
Martin H; Redfern A
Cancer Med; 2024 Jan; 13(1):. PubMed ID: 38186326
[TBL] [Abstract][Full Text] [Related]
17. Breast density reduction as a predictor for prognosis in premenopausal women with estrogen receptor-positive breast cancer: an exploratory analysis of the updated ASTRRA study.
Bae SJ; Kim HJ; Kim HA; Ryu JM; Park S; Lee EG; Im SA; Jung Y; Park MH; Park KH; Kang SH; Park E; Kim SY; Lee MH; Kim LS; Lee A; Noh WC; Gwark S; Kim S; Jeong J
Int J Surg; 2024 Feb; 110(2):934-942. PubMed ID: 38000057
[TBL] [Abstract][Full Text] [Related]
18. Artificial Intelligence in Breast Cancer Diagnosis and Personalized Medicine.
Ahn JS; Shin S; Yang SA; Park EK; Kim KH; Cho SI; Ock CY; Kim S
J Breast Cancer; 2023 Oct; 26(5):405-435. PubMed ID: 37926067
[TBL] [Abstract][Full Text] [Related]
19. Changes in Automated Mammographic Breast Density Can Predict Pathological Response After Neoadjuvant Chemotherapy in Breast Cancer.
Ahn JH; Go J; Lee SJ; Kim JY; Park HS; Kim SI; Park BW; Park VY; Yoon JH; Kim MJ; Park S
Korean J Radiol; 2023 May; 24(5):384-394. PubMed ID: 37133209
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
